Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2015

View Archived Issues

Bayer Schering Pharma discloses CCR2 antagonists

Vectus Biosystems patents novel compounds for hypertension and fibrosis

BIIB-037 shows promising results as a disease-modifying treatment in AD patients

4E-T identified as potential prognostic marker in breast carcinoma

JCR Pharma prepares for clinical development of sustained growth hormone formulation

PI3Kbeta inhibitors show promise for the treatment of PTEN-mutated tumors

Pharmacyclics patents BTK inhibitors

Daiichi Sankyo reports development of novel Nrf2 activators by biotransformation

Recro Pharma acquires injectable meloxicam for pain

Cipher Pharmaceuticals acquires dermatology company INNOCUTIS

Merck & Co. discloses novel HCV NS5A inhibitor

DiscoveryBioMed developing dual-action small-molecule monotherapy for cystic fibrosis

SBIR grant supports Xeris' development of stable non-aqueous glucagon for congenital hyperinsulinism

Lummy HK licenses Chinese rights to AGS-003 and Argos' Arcelis technology

Menarini licenses resminostat for development and marketing in Asia-Pacific excluding Japan

Astellas to collaborate with Ventana Medical Systems on companion diagnostic tests

Esperas Pharma launched to develop anticancer compound discovered at Lilly

Roche introduces mGlu4 receptor PAMs

Sunshine Lake Pharma patent describes SGLT2 inhibitors

Bayer Schering Pharma presents FXIa inhibitors

Columbia Laboratories changes name to Juniper Pharmaceuticals

Soligenix and FDA agree on protocol for phase III trial of SGX-203 for pediatric Crohn's disease

EMA approves compassionate use of OMS-721 in patients with aHUS

FDA grants orphan drug status to tremelimumab for malignant mesothelioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...